<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03865875</url>
  </required_header>
  <id_info>
    <org_study_id>18-635</org_study_id>
    <nct_id>NCT03865875</nct_id>
  </id_info>
  <brief_title>Pilot Study of a Multimodal Prehabilitation Pancreatic Cancer Program</brief_title>
  <official_title>Pilot Study of a Multimodal Prehabilitation Pancreatic Cancer Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to explore the benefits of an exercise and nutrition program
      during total neoadjuvant therapy (TNT) in preparation for surgery for participants that have
      pancreatic ductal adenocarcinoma (PDAC)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study involves an exercise and nutrition program that will consist of twice
      weekly exercise sessions and discussion with a nutritionist with possible nutrition
      supplementation.

      The names of the study interventions involved in this study are:

        -  Exercise Intervention

        -  Nutrition Intervention

      The research study procedures include: screening for eligibility, study evaluations, and
      follow up visits.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2019</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants to complete prehabilitation program</measure>
    <time_frame>1 year</time_frame>
    <description>At least 50% (95% confidence interval +/- 16%) of participants will complete 50% of the components of the prehabilitation program.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Multimodal Prehabilitation Program</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pretreatment exercise program and nutrition program
-The prehabilitation intervention will include the following components: (1) a standardized fitness program and (2) nutritional counseling and optimization. Patients are enrolled in the program within 8 weeks of being diagnosed and continued until operation</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise Program</intervention_name>
    <description>Participants will start the exercise program within 2 weeks of enrollment and will continue until surgery. This program will consist of twice weekly individualized sessions with a trainer.</description>
    <arm_group_label>Multimodal Prehabilitation Program</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Nutrition Program</intervention_name>
    <description>Each patient enrolled will undergo nutritional assessment at their initial post-enrollment visit to develop an individualized nutrition plan to be implemented up until when the patient undergoes surgery.</description>
    <arm_group_label>Multimodal Prehabilitation Program</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Adults age 18 years or older.

          -  Diagnosed within 8 weeks with upfront resectable, borderline resectable, or locally
             advanced unresectable PDAC as defined by the National Comprehensive Cancer Network
             (NCCN).

          -  Planning to undergo TNT at MGH.

          -  Planning to receive modified FOLFIRINOX for neoadjuvant chemotherapy.

          -  Planning to undergo surgical resection of PDAC at MGH.

          -  Verbal fluency in English.

        Exclusion Criteria

          -  Metastatic disease.

          -  Previous treatment for pancreas adenocarcinoma and no prior therapy for any cancer
             within 5 years.

          -  Known history of cognitive or psychologic impairment.

          -  Known history of physical impairment such as immobility, use of walking aids, or
             required wheelchair use.

          -  Known history of the following orthopedic comorbidities: advanced osteoarthritis or
             rheumatoid arthritis, mobility-limiting amputations, orthopedic injuries, or
             widespread chronic pain (e.g. fibromyalgia).

          -  Known history of the following pulmonary comorbidities: severe chronic obstructive
             pulmonary disease (COPD) defined as FEV1 â‰¤ 50%, emphysema, interstitial lung disease,
             and/or use of supplemental oxygen.

          -  Known history of the following cardiovascular comorbidities: uncontrolled
             hypertension, severe congestive heart failure (NYHA Class IV), and/or myocardial
             infarction within the last 6 months.

          -  Inability to tolerate diet through routine oral routes and/or patients with strict
             nutritional restrictions, allergies, and/or dietary preferences.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Motaz Qadan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Naomi Sell, MD, MHS</last_name>
    <phone>650-868-9440</phone>
    <email>nsell@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Motaz Qadan, MD, PhD</last_name>
    <phone>617-643-5153</phone>
    <email>mqadan@mgh.harvard.edu</email>
  </overall_contact_backup>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 5, 2019</study_first_submitted>
  <study_first_submitted_qc>March 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2019</study_first_posted>
  <last_update_submitted>March 5, 2019</last_update_submitted>
  <last_update_submitted_qc>March 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Motaz Qadan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pancreatic Ductal Adenocarcinoma</keyword>
  <keyword>Total Neoadjuvant Therapy</keyword>
  <keyword>Prehabilitation</keyword>
  <keyword>Exercise</keyword>
  <keyword>Nutrition</keyword>
  <keyword>Optimization</keyword>
  <keyword>Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data can be shared no earlier than 1 year following the date of publication</ipd_time_frame>
    <ipd_access_criteria>MGH - Contact the Partners Innovations team at http://www.partners.org/innovation</ipd_access_criteria>
    <ipd_url>http://www.dfhcc.harvard.edu/crs-resources/ODQ_Documents/02_CT.GOV_CTRP/Guidance_on_Data_Sharing.pdf</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

